

CORPORATE NEWS

MeVis Medical Solutions AG
Caroline-Herschel-Straße 1
28359 Bremen
Germany

Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de

MeVis Medical Solutions AG: Domination and profit and loss transfer agreement registered with the Commercial Register

Bremen, October 23, 2015 – The MeVis Medical Solutions AG announces today that the domination and profit and loss transfer agreement concluded on August 10, 2015 between the VMS Deutschland Holdings GmbH as the controlling company and MeVis Medical Solutions AG as the controlled company has been registered with the Commercial Register of the Bremen Local Court on October 20, 2015 and has thus become legally effective. The registration in the Commercial Register has been published by the Bremen Local Court on October 21, 2015. The shareholders of the MeVis Medical Solutions AG already approved the domination and profit and loss transfer agreement with a large majority in the extraordinary general meeting on September 29, 2015.

Under the domination and profit and loss transfer agreement and upon request of each outside shareholder the VMS Deutschland Holdings GmbH is obliged to acquire MeVis shares against a cash settlement payment in the amount of EUR 19.77 per MeVis share.

Optionally, the VMS Deutschland Holdings GmbH guarantees the outside shareholders of MeVis Medical Solutions AG, who chose not to accept the settlement payment offer, for the duration of the domination and profit and loss transfer agreement an annual compensation payment for each MeVis Medical Solutions AG fiscal year and each registered share in MeVis Medical Solutions AG, representing a pro rata amount of the share capital of EUR 1.00 per share, in the amount of EUR 1.13 gross / EUR 0.95 net.

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.